ClinicalTrials.gg
CompletedNCT01075282AWARD-2Updated Jan 16, 2015Results posted

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

A Phase 3 interventional study of Insulin Glargine and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 78 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
6th of 54
810 · median 159
Started
2010
with 6 others
Phase 3
22 of 54
1 open now
Registered
6th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.

Read the detailed description

Rescue therapy refers to 1 of 2 types of additional therapy, each given for a different reason: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified efficacy analyses.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes not well controlled on 1, 2, or 3 oral antidiabetic medications (at least one of them must be metformin and/or a sulfonylurea)

    1. Glycosylated () greater than or equal to 7 and less than or equal to 11 if taking 1 oral antidiabetic medication
    2. HbA1c greater than or equal to 7 and less than or equal to 10 if on 2 or 3 oral antidiabetic medications
  • Accept treatment with metformin and glimepiride throughout the study, as per protocol
  • Willing to inject subcutaneous medication once weekly for LY2189265 or once daily for Insulin Glargine.
  • Stable weight for 3 months prior to screening
  • (BMI) between 23 and 45 kilograms per square meter (kg/m\^2)
  • Females of child bearing potential must test negative for pregnancy at screening by serum pregnancy test and be willing to use a reliable method of during the study and for 1 month following the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes
  • equal to or less than 6.5 at randomization
  • Chronic insulin use
  • Taking drugs to promote weight loss by prescription or over the counter
  • Taking systemic for greater than 14 days except for topical, eye, nasal, or inhaled
  • History of Heart Failure New York Heart Classification III or IV, or acute myocardial infarction, or stroke within 2 months of screening
  • Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking drugs that directly affect GI motility
  • Hepatitis or liver disease or (alanine transaminase) greater than 3.0 of upper normal limit
  • Acute or chronic pancreatitis of any form
  • Renal disease (kidney) with a serum creatinine of greater than or equal to 1.5 milligrams per deciliter (mg/dL) for males and greater than or equal to 1.4 mg/dL for females, or a of less than 60 milliliters per minute (ml/min)
  • History (includes family) of type 2A or 2B Multiple Endocrine Neoplasia (MEN 2A or 2B) or medullary c-cell hyperplasia or thyroid cancer
  • A serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/ml) at screening
  • Significant active disease such as Lupus or Rheumatoid Arthritis
  • History of or active except skin or in situ cervical or prostate cancer for within last 5 years
  • Sickle cell, hemolytic anemia, or other hematological condition that may interfere with HbA1c testing
  • Organ transplant except cornea
  • Have enrolled in another clinical trial within the last 30 days
  • Have previously signed an or participated in a LY2189265 study
  • Have taken a glucagon-like peptide 1 (GLP-1) receptor agonist within the 3 months prior to screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    LY2189265 1.5 mg

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    Drug: LY2189265 · Drug: Metformin · Drug: Glimepiride

  • Experimental
    LY2189265 0.75 mg

    LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    Drug: LY2189265 · Drug: Metformin · Drug: Glimepiride

  • Active comparator
    Insulin Glargine

    Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    Drug: Insulin Glargine · Drug: Metformin · Drug: Glimepiride

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 26 weeks, and 78 weeks

  2. Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks

    Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

    Time frame: 26, 52, and 78 weeks

  3. Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks

    Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

    Time frame: 26, 52, and 78 weeks

  4. Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

    The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  5. Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

    The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52, and 78 weeks

  6. Change From Baseline to 52 and 78 Weeks in Glucagon Concentration

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 52, and 78 weeks

  7. Change From Baseline to 26, 52 and 78 Weeks for Body Weight

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  8. Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index

    Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  9. Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension

    The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

    Time frame: Baseline, 26, 52, and 78 weeks

  10. Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living

    The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  11. Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception

    The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  12. Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey

    The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  13. Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: 26, 52, and 78 weeks

  14. Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26, 52, and 78 weeks

  15. Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26, 52, and 78 weeks

  16. Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks

    Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks.

    Time frame: 26, 52, and 78 weeks

  17. Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes

    Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, 26, 52, and 78 weeks

  18. Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26, 52, and 78 weeks

  19. Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin

    Time frame: Baseline, 26, 52, and 78 weeks

  20. Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks

    Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26, 52, and 78 weeks

  21. Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate

    Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  22. Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure

    Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  23. Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate

    Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  24. Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 78 weeks

  25. Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)

    LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.

    Time frame: Baseline, 26, 52, 78, and 83 weeks

07

Results

Posted Jan 16, 2015

Participant flow

Participant flow — Overall Study
MilestoneLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Started273272265
Received at least one dose of study drug273272262
Completed242243238
Not completed312927
Withdrew: Withdrawal by subject11711
Withdrew: Adverse event985
Withdrew: Entry criteria not met320
Withdrew: Lost to follow-up333
Withdrew: Physician decision333
Withdrew: Lack of efficacy110
Withdrew: Treatment non-compliance122
Withdrew: Protocol violation021
Withdrew: Death012

Outcome measures

PrimaryChange From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobinLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)-1.08 ± 0.06-0.76 ± 0.06-0.63 ± 0.06
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.45 · 95% CI -0.60 to -0.29
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.13 · 95% CI -0.29 to 0.02
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.45 · 95% CI -0.60 to -0.29
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = 0.05 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.13 · 95% CI -0.29 to 0.02
SecondaryChange From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 26 weeks, and 78 weeks
Reported as:
Least squares mean · percent
Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
percentLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=263, 266, 258)-1.16 ± 0.06-0.89 ± 0.05-0.65 ± 0.06
78 weeks (n=263, 267, 259)-0.90 ± 0.07-0.62 ± 0.07-0.59 ± 0.07
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.51 · 95% CI -0.65 to -0.37
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.24 · 95% CI -0.38 to -0.10
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.51 · 95% CI -0.65 to -0.37
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.24 · 95% CI -0.38 to -0.10
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 78 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.31 · 95% CI -0.50 to -0.13
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 78 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.03 · 95% CI -0.21 to 0.15
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 78 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.31 · 95% CI -0.50 to -0.13
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = 0.378 (Treatment comparison at 78 weeks. P-value is adjusted for multiplicity, based on tree-gatekeeping strategy, and compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.03 · 95% CI -0.21 to 0.15
SecondaryNumber of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

Time frame:
26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=263, 266, 258)15312284
52 weeks (n=263, 267, 259)1409980
78 weeks (n=263, 267, 259)1299179
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.) · Odds ratio (or): 4.61 · 95% CI 2.98 to 7.11
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.) · Odds ratio (or): 2.13 · 95% CI 1.41 to 3.24
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 52 weeks.) · Odds ratio (or): 3.76 · 95% CI 2.45 to 5.75
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = 0.098 (Treatment comparison at 52 weeks.) · Odds ratio (or): 1.42 · 95% CI 0.94 to 2.15
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 78 weeks.) · Odds ratio (or): 2.77 · 95% CI 1.85 to 4.14
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = 0.334 (Treatment comparison at 78 weeks.) · Odds ratio (or): 1.22 · 95% CI 0.82 to 1.82
SecondaryNumber of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.

Time frame:
26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=263, 266, 258)977440
52 weeks (n=263, 267, 259)716035
78 weeks (n=263, 267, 259)745943
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.) · Odds ratio (or): 4.70 · 95% CI 2.90 to 7.63
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.) · Odds ratio (or): 2.54 · 95% CI 1.57 to 4.11
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 52 weeks.) · Odds ratio (or): 2.97 · 95% CI 1.81 to 4.85
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = 0.004 (Treatment comparison at 52 weeks.) · Odds ratio (or): 2.07 · 95% CI 1.26 to 3.39
  • LY2189265 1.5 mg vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 78 weeks.) · Odds ratio (or): 2.27 · 95% CI 1.44 to 3.57Treatment comparison at 78 weeks.
  • LY2189265 0.75 mg vs Insulin Glargine · Regression, Logistic · p = 0.073 (Treatment comparison at 78 weeks.) · Odds ratio (or): 1.53 · 95% CI 0.96 to 2.42
SecondaryChange From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
millimoles per liter (mmol/L)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=199, 204, 190)-1.79 ± 0.10-1.46 ± 0.10-1.58 ± 0.10
52 weeks (n=180, 185, 176)-1.69 ± 0.11-1.32 ± 0.11-1.44 ± 0.11
78 weeks (n=172, 164, 168)-1.55 ± 0.13-1.15 ± 0.12-1.47 ± 0.13
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.109 (Treatment comparison at 26 weeks.)
  • LY2189265 0.75 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.335 (Treatment comparison at 26 weeks.)
  • LY2189265 1.5 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.091 (Treatment comparison at 52 weeks.)
  • LY2189265 0.75 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.400 (Treatment comparison at 52 weeks.)
  • LY2189265 1.5 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.641 (Treatment comparison at 78 weeks.)
  • LY2189265 0.75 mg vs Insulin Glargine · Mixed Models Analysis · p = 0.055 (Treatment comparison at 78 weeks.)
SecondaryChange From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52, and 78 weeks
Reported as:
Least squares mean · percentage of HOMA2
Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
percentage of HOMA2LY2189265 1.5 mgLY2189265 0.75 mg
HOMA2-%B, 52 weeks (n=175, 181)29.95 ± 4.6124.60 ± 4.51
HOMA2-%B, 78 weeks (n=167, 165)28.54 ± 4.7815.66 ± 4.75
HOMA2-%S, 52 weeks (n=175,181)-2.89 ± 1.21-2.66 ± 1.19
HOMA2-%S, 78 weeks (n=167, 165)-2.64 ± 1.23-3.62 ± 1.23
SecondaryChange From Baseline to 52 and 78 Weeks in Glucagon Concentration

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 52, and 78 weeks
Reported as:
Least squares mean · picomoles per liter (pmol/L)
Change From Baseline to 52 and 78 Weeks in Glucagon Concentration
picomoles per liter (pmol/L)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
52 weeks (n=232, 231, 228)-3.91 ± 0.47-3.31 ± 0.47-3.85 ± 0.47
78 weeks (n=235, 235, 232)-3.57 ± 0.47-3.37 ± 0.47-3.65 ± 0.47
SecondaryChange From Baseline to 26, 52 and 78 Weeks for Body Weight

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline to 26, 52 and 78 Weeks for Body Weight
kilogram (kg)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks-1.82 ± 0.20-1.47 ± 0.201.01 ± 0.20
52 weeks-1.87 ± 0.24-1.33 ± 0.241.44 ± 0.24
78 weeks-1.96 ± 0.26-1.54 ± 0.261.28 ± 0.26
Statistical analysis
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: 2.83 · 95% CI 2.33 to 3.33
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: 2.48 · 95% CI 1.99 to 2.99
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: 3.31 · 95% CI 2.71 to 3.90
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: 2.77 · 95% CI 2.17 to 3.36
  • LY2189265 1.5 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 78 weeks.) · Ls mean difference: 3.24 · 95% CI 2.59 to 3.89
  • LY2189265 0.75 mg vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 78 weeks.) · Ls mean difference: 2.82 · 95% CI 2.17 to 3.46
SecondaryChange From Baseline to 26, 52 and 78 Weeks for Body Mass Index

Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · kilograms per square meter (kg/m^2)
Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index
kilograms per square meter (kg/m^2)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=257, 261, 245)-0.64 ± 0.07-0.50 ± 0.070.44 ± 0.07
52 weeks (n=250, 252, 238)-0.64 ± 0.08-0.39 ± 0.080.62 ± 0.08
78 weeks (n=246, 244, 238)-0.64 ± 0.09-0.39 ± 0.090.59 ± 0.10
SecondaryChange From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension

The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension
units on a scaleLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
EQ-5D UK, 26 weeks (n=257, 254, 249)0.01 ± 0.010.00 ± 0.01-0.01 ± 0.01
EQ-5D UK, 52 weeks (n=259, 260, 253)0.01 ± 0.010.00 ± 0.01-0.04 ± 0.01
EQ-5D UK, 78 weeks (n=259, 260, 253)0.01 ± 0.010.00 ± 0.010.00 ± 0.01
VAS, 26 weeks (n=253, 252, 243)3.3 ± 0.833.4 ± 0.840.8 ± 0.86
VAS, 52 weeks (n=260, 258, 252)3.2 ± 0.852.3 ± 0.851.1 ± 0.88
VAS, 78 weeks (n=260, 258, 252)3.8 ± 0.853.2 ± 0.852.2 ± 0.89
SecondaryChange From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living

The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living
units on a scaleLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=256, 256, 248)0.7 ± 0.300.1 ± 0.30-0.3 ± 0.30
52 weeks (n=260, 261, 249)0.9 ± 0.310.4 ± 0.31-0.6 ± 0.32
78 weeks (n=260, 261, 249)1.0 ± 0.310.3 ± 0.31-0.3 ± 0.32
SecondaryChange From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception
units on a scaleLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=258, 258, 251)0.1 ± 0.160.2 ± 0.16-0.1 ± 0.16
52 weeks (n=260, 261, 252)0.5 ± 0.160.2 ± 0.160.1 ± 0.16
78 weeks (n=260, 261, 252)0.5 ± 0.160.3 ± 0.150.1 ± 0.16
SecondaryChange From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey

The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey
units on a scaleLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=255, 255, 244)-2.8 ± 0.95-2.4 ± 0.960.3 ± 0.98
52 weeks (n=258, 259, 245)-4.2 ± 0.83-4.1 ± 0.83-1.0 ± 0.86
78 weeks (n=258, 259, 245)-4.6 ± 0.82-4.7 ± 0.82-2.0 ± 0.85
SecondaryNumber of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks160146137
52 weeks189175175
78 weeks201188192
SecondaryNumber of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26, 52, and 78 weeks
Reported as:
Number · events
Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
eventsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Severe HE, 26 weeks101
Severe HE, 52 weeks102
Severe HE, 78 weeks202
Documented symptomatic HE, 26 weeks311315447
Documented symptomatic HE, 52 weeks515444789
Documented symptomatic HE, 78 weeks6075151033
Asymptomatic HE, 26 weeks500484609
Asymptomatic HE, 52 weeks7577091093
Asymptomatic HE, 78 weeks8849111358
Nocturnal HE, 26 weeks145117240
Nocturnal HE, 52 weeks185147519
Nocturnal HE, 78 weeks215184635
Probable symptomatic HE, 26 weeks111920
Probable symptomatic HE, 52 weeks172422
Probable symptomatic HE, 78 weeks202826
SecondaryRate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26, 52, and 78 weeks
Reported as:
Mean · events per participant per year
Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
events per participant per yearLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Severe HE, 26 weeks0.01 ± 0.120.00 ± 0.000.01 ± 0.12
Severe HE, 52 weeks0.00 ± 0.060.00 ± 0.000.01 ± 0.09
Severe HE, 78 weeks0.01 ± 0.060.00 ± 0.000.01 ± 0.06
Documented symptomatic HE, 26 weeks2.35 ± 5.412.52 ± 6.423.64 ± 6.63
Documented symptomatic HE, 52 weeks2.03 ± 4.161.97 ± 5.313.34 ± 5.91
Documented symptomatic HE, 78 weeks1.67 ± 3.581.66 ± 4.963.03 ± 5.63
Asymptomatic HE, 26 weeks3.79 ± 8.013.58 ± 7.704.82 ± 11.43
Asymptomatic HE, 52 weeks3.08 ± 6.972.68 ± 5.404.41 ± 8.72
Asymptomatic HE, 78 weeks2.56 ± 5.902.38 ± 4.953.80 ± 7.24
Nocturnal HE, 26 weeks1.23 ± 3.840.96 ± 3.531.86 ± 4.84
Nocturnal HE, 52 weeks0.90 ± 3.130.65 ± 2.652.07 ± 4.67
Nocturnal HE, 78 weeks0.77 ± 2.970.59 ± 2.471.81 ± 4.12
Probable symptomatic HE, 26 weeks0.08 ± 0.590.14 ± 1.390.15 ± 0.87
Probable symptomatic HE, 52 weeks0.07 ± 0.400.09 ± 0.990.08 ± 0.47
Probable symptomatic HE, 78 weeks0.05 ± 0.320.07 ± 0.670.07 ± 0.37
SecondaryNumber of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks

Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks.

Time frame:
26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks240
52 weeks11208
78 weeks243416
SecondaryChange From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Median · units/liter
Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes
units/literLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Amylase (total), 26 weeks4.000 (-4.000 to 13.000)4.000 (-3.000 to 11.000)2.000 (-5.000 to 8.000)
Amylase (total), 52 weeks4.000 (-4.000 to 11.000)5.000 (-3.000 to 13.000)3.000 (-5.000 to 9.000)
Amylase (total), 78 weeks4.000 (-4.000 to 13.000)4.000 (-3.000 to 12.000)1.000 (-7.000 to 9.000)
Amylase (pancreas-derived), 26 weeks3.000 (-1.000 to 8.000)3.000 (0.000 to 7.000)1.000 (-2.000 to 4.000)
Amylase (pancreas-derived), 52 weeks3.000 (-1.000 to 8.000)3.000 (-1.000 to 7.000)1.000 (-2.000 to 6.000)
Amylase (pancreas-derived), 78 weeks2.000 (-2.000 to 7.000)2.000 (-1.000 to 7.000)0.000 (-3.000 to 4.000)
Lipase, 26 weeks5.000 (-4.000 to 15.000)5.000 (-1.000 to 15.000)-1.000 (-6.000 to 5.000)
Lipase, 52 weeks4.000 (-3.000 to 12.000)4.000 (-2.000 to 11.000)-1.000 (-8.000 to 6.000)
Lipase, 78 weeks4.000 (-3.000 to 14.000)4.000 (-1.000 to 13.000)-2.000 (-8.000 to 5.000)
SecondaryNumber of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks110
52 weeks210
78 weeks210
SecondaryChange From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin
Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Mean · picogram/milliliter
Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin
picogram/milliliterLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=266, 267, 258)0.163 ± 1.310.097 ± 1.200.149 ± 1.30
52 weeks (n=266, 269, 259)0.128 ± 1.200.132 ± 1.320.176 ± 1.62
78 weeks (n=267, 269, 259)0.086 ± 1.310.035 ± 1.200.151 ± 1.73
SecondaryNumber of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks

Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26, 52, and 78 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks
participantsLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
Any CV event, 26 weeks213
Any fatal CV event, 26 weeks000
Any non-fatal CV event, 26 weeks213
Any CV event, 52 weeks346
Any fatal CV event, 52 weeks001
Any non-fatal CV event, 52 weeks345
Any CV event, 78 week369
Any fatal CV event, 78 week011
Any non-fatal CV event, 78 week368
SecondaryChange in Baseline to 26, 52 and 78 Weeks on Pulse Rate

Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate
beats per minute (bpm)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=257, 260, 245)1.56 ± 0.490.74 ± 0.48-1.21 ± 0.50
52 weeks (n=250, 252, 240)1.29 ± 0.500.51 ± 0.49-0.52 ± 0.51
78 weeks (n=246, 244, 238)1.31 ± 0.500.61 ± 0.50-0.91 ± 0.51
SecondaryChange From Baseline to 26, 52, and 78 Weeks on Blood Pressure

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · milliliter of mercury (mmHG)
Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure
milliliter of mercury (mmHG)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
SBP, 26 weeks (n=257, 261, 245)-1.28 ± 0.78-1.60 ± 0.78-0.03 ± 0.80
SBP, 52 weeks (n=250, 252, 240)0.17 ± 0.810.09 ± 0.800.51 ± 0.83
SBP, 78 weeks (n=246, 244, 238)-0.70 ± 0.85-0.59 ± 0.850.51 ± 0.87
DBP, 26 weeks (n=257, 261, 245)-0.16 ± 0.49-0.17 ± 0.48-0.29 ± 0.50
DBP, 52 weeks (n=250, 252, 240)-0.26 ± 0.48-0.19 ± 0.47-0.93 ± 0.49
DBP, 78 weeks (n=246, 244, 238)-0.44 ± 0.52-0.36 ± 0.52-1.04 ± 0.53
SecondaryChange From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate

Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate
beats per minute (bpm)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
26 weeks (n=241, 247, 231)2.64 ± 0.5390.90 ± 0.529-1.24 ± 0.549
52 weeks (n=232, 242, 231)2.41 ± 0.5640.38 ± 0.551-1.01 ± 0.568
78 weeks (n=223, 222, 225)2.49 ± 0.5920.47 ± 0.588-0.26 ± 0.594
SecondaryChange From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 78 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)LY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
QTcF interval, 26 weeks (n=240, 245, 229)-1.71 ± 0.939-0.10 ± 0.9261.24 ± 0.962
QTcF interval, 52 weeks (n=231, 240, 228)1.55 ± 1.0741.34 ± 1.0543.70 ± 1.088
QTcF interval, 78 weeks (n=221, 220, 222)1.66 ± 1.0453.44 ± 1.0394.44 ± 1.053
PR interval, 26 weeks (n=240, 245, 229)2.78 ± 0.8492.33 ± 0.8361.24 ± 0.873
PR interval, 52 weeks (n=230, 240, 227)2.61 ± 0.8531.88 ± 0.8351.50 ± 0.868
PR interval, 78 weeks (n=221, 220, 222)2.62 ± 1.0343.27 ± 1.0261.21 ± 1.043
SecondaryNumber of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)

LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.

Time frame:
Baseline, 26, 52, 78, and 83 weeks
Reported as:
Number · participants
Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)
participantsLY2189265 1.5 mg and 0.75 mg
26 weeks11
52 weeks3
78 weeks1
83 weeks0

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2189265 1.5 mg—32/273 (11.7%)199/273 (72.9%)
LY2189265 0.75 mg—28/272 (10.3%)190/272 (69.9%)
Insulin Glargine—33/262 (12.6%)187/262 (71.4%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
OverdoseInjury, poisoning and procedural complications3/2730/2720/262
HyperglycaemiaMetabolism and nutrition disorders3/2730/2720/262
Maternal exposure during pregnancyInjury, poisoning and procedural complications0/1290/1361/128
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1290/1361/128
Coronary artery diseaseCardiac disorders1/2730/2722/262
CholelithiasisHepatobiliary disorders1/2731/2722/262
HypoglycaemiaMetabolism and nutrition disorders2/2730/2722/262
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2730/2722/262
Acute myocardial infarctionCardiac disorders0/2732/2720/262
Angina unstableCardiac disorders0/2732/2720/262
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLY2189265 1.5 mgLY2189265 0.75 mgInsulin Glargine
NauseaGastrointestinal disorders42/27322/2724/262
DiarrhoeaGastrointestinal disorders29/27326/27215/262
NasopharyngitisInfections and infestations16/27312/27224/262
HeadacheNervous system disorders22/2739/27213/262
DyspepsiaGastrointestinal disorders19/2739/2726/262
VomitingGastrointestinal disorders18/27310/2723/262
Upper respiratory tract infectionInfections and infestations15/27311/27217/262
Urinary tract infectionInfections and infestations12/27317/27215/262
BronchitisInfections and infestations9/2737/27214/262
InfluenzaInfections and infestations12/27313/27214/262

Baseline characteristics

Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.

Age, Continuous
Age, Continuous(years)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Mean56.24 ± 9.7656.56 ± 9.2757.21 ± 9.3856.66 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Female129136128393
Male144136134414
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Hispanic or Latino989697291
Not Hispanic or Latino175176165516
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
American Indian or Alaska Native29312989
Asian484643137
Native Hawaiian or Other Pacific Islander0000
Black or African American1124
White193193184570
More than one race2147
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Taiwan13131238
Slovakia1102
Greece66719
Spain10121335
Italy2316
India30272784
France2316
Czech Republic12141339
Hungary16161547
Mexico29282784
Canada26252475
Argentina555454163
Belgium75315
Brazil65718
Poland16181751
Croatia34411
Romania23222267
Australia13131339
Sweden2013
Korea, Republic of1315
Body Weight
Body Weight(kilograms)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Mean85.13 ± 17.9086.18 ± 18.1587.66 ± 19.6286.31 ± 18.56
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Mean31.23 ± 5.2131.51 ± 5.4131.91 ± 5.7631.55 ± 5.46
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)LY2189265 1.5 mgLY2189265 0.75 mgInsulin GlargineTotal
Mean8.18 ± 1.038.13 ± 0.988.10 ± 0.958.14 ± 0.99

2 further baseline measures are reported on the registry.

08

Study locations

78 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1425AGC, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, C1417EYG, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Córdoba, 5006, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mendoza, 5500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wollongong, New South Wales 2500, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brisbane, Queensland 4029, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Keswick, South Australia 5035, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    East Ringwood, Victoria 3135, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heidelberg, Victoria 3081, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gribomont, 6887, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halen, 3545, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Joinville, 89201-260, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 05403-900, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmonton, Alberta T5J 3N4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coquitlam, British Columbia V3K 3P4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3E 3P4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. John, Newfoundland and Labrador A1E 2C2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Markham, Ontario L6B 0P9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mississauga, Ontario L5M 2V8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2W 1R7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1G 5K2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osijek, 31000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Slavonski Brod, 35 000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, 10000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Holesov, 769 01, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 140 59, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corbeil-Essonnes, 91106, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dijon, 21079, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44093, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pessac, 33604, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tours, 37044, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1036, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mako, 6900, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mosonmagyarovar, 9200, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szekesfehervar, 8000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aligarh, 202002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560003, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chennai, 600029, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indore, 452002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jaipur, 302001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400053, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patna, 800 020, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50141, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucheon, 420-717, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ilsan, 411706, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 614-735, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coatzacoalcos, 96400, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cuernavaca, 62250, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44656, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64570, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-404, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydogoszcz, 85-094, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 31-261, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 71-455, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-127, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baia Mare, 430123, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020045, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800587, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oradea, 410025, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kosice, 04001, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alicante, 03114, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avila, 05004, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palencia, 34005, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Requena, 46340, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göteborg, 41345, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Helsingborg, 25187, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lund, 22185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stockholm, 11157, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiayi City, 600, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 807, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11031, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yung-Kang, Tainan, 710, Taiwan
09

References and documents

Publications

  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
  • Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625. Epub 2015 Jun 18. PubMed 26089386 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of May 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 2 years 8 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2010
First posted
Feb 25, 2010
Start
Feb 2010
Primary completionActual
May 2012
CompletionActual
Nov 2012
Results delay requested
Sep 18, 2012
Results first posted
Jan 16, 2015
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01075282
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Feb 2010
Primary completion
May 2012
Completion
Nov 2012
Results posted
Jan 16, 2015
Last update
Jan 16, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion